Scott Morenstein

Managing Director

Mr. Morenstein joined Valence Advantage Life Sciences in 2012. Previously, Mr. Morenstein was a Principal at Caxton Advantage which he joined in 2007. Mr. Morenstein has 13 years of experience in the life sciences industry. Prior to joining Caxton Advantage, Mr. Morenstein was an investment banker and founding member of Seaview Securities, a boutique investment bank focused on life sciences mergers and acquisitions and private placements. Previously, Mr. Morenstein was also a healthcare investment banker and equity research analyst covering the biotechnology sector at Lehman Brothers. While at Caxton Advantage, Mr. Morenstein was actively involved in the fund’s investments in Gemin X Pharmaceuticals, Sunesis Pharmaceuticals, and ArQule. Scott served as a Director on the Board of Caxton Advantage portfolio company, Gemin X Pharmaceuticals. Scott received an MBA from Harvard Business School and a BA from the University of Pennsylvania with a degree in the Biological Basis of Behavior with a Concentration in the Physiology of Neural Systems.

A. Rachel Leheny, Ph.D.

 

Eric W. Roberts

 

Jay Cecil

 

Rob Ferraioli

 

Devon E. Coger